SCHEMBL3842313

SCHEMBL3842313

Cc1ccc2c(ccn2NC(=O)C2=CCCN(CCN3CCN(C)CC3)C2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.36
CHRNA7 P36544 2/20 0.36
PRMT5 O14744 1/20 0.35
RAD52 P43351 2/20 0.35
KCNH2 Q12809 1/20 0.35
HTR6 P50406 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
POLB P06746 1/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3841078 0.89 HTR7 (0.43) HTR7HTR6MAPK1POLBKDM4E
SCHEMBL3837780 0.87 SIGMAR1 (0.38) HTR7HTR6MAPK1KDM4EALDH1A1
SCHEMBL3837840 0.87 HTR7 (0.44) HTR7PRMT5HTR6TSHRPOLB
SCHEMBL3841799 0.80 SLC6A1 (0.37) L3MBTL1HTR6TSHRMAPK1KDM4E
SCHEMBL3841744 0.79 HPGD (0.38) RAD52HTR6TSHRMAPK1POLB
SCHEMBL3843600 0.78 HTR6 (0.35) HTR7PRMT5RAD52KCNH2HTR6
SCHEMBL3840170 0.77 KDM4E (0.35) MAPK1KDM4EALDH1A1
SCHEMBL3840185 0.76 THRB (0.42) HTR6HRH4
SCHEMBL3830302 0.76 CHRM2 (0.42) HTR6POLBKDM4EALDH1A1HSD17B10
SCHEMBL3837835 0.75 HTR2C (0.41) HTR6TSHRMAPK1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298813-A1 USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES LES LABORATOIRES SERVIER (FR) 2009-12-03 US disclosed
CN-101578100-A Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases SERVIER LAB (FR) 2009-11-11 CN disclosed
EP-1931341-B1 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS SERVIER LAB (FR) 2009-11-04 EP disclosed
US-20090258883-A1 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds LES LABORATOIRES SERVIER (FR) 2009-10-15 US disclosed
CN-101257905-A Novel 1h-indole-pyridinecarboxamide derivatives and 1h-indole-piperidinecarboxamide and their use as hydroxalase tyrosine inducers SERVIER LAB (FR) 2008-09-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298813-A1 USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES NLN, GAP43, SNCA HTR7 1269/4885L3MBTL1 2676/4885CHRNA7 225/4885
US-20090258883-A1 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds IDO1, AHR, IDO2 HTR7 194/4885L3MBTL1 2761/4885CHRNA7 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.